indazoles has been researched along with tamoxifen in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Becker, H; Hoffmann, L; Köllermann, M; Müller, W; Possinger, K; Schlichter, A; Schmoll, E; Stahl, M; Wagner, H; Weidenhammer, W | 1 |
| Feustel, PJ; Kimelberg, HK; Mongin, AA; Osuka, K; Tranmer, BI | 1 |
| Andreatini, R; Chioca, LR; Correia, D; Pereira, M; Pizzolatti, MG; Santos, AR; Siba, IP; Vital, MA | 1 |
| Brennan, KR; Clarke, RB; Gregson, HJ; Harrison, H; Landberg, G; Rogerson, L | 1 |
| Aguilar, H; Balart, J; Barril, X; Beijersbergen, RL; Bonifaci, N; Bostner, J; Brunet, J; Burnstein, KL; Bustelo, XR; Caizzi, L; Carlson, KE; Clarke, R; Climent, F; Di Croce, L; Esteller, M; Extremera, AI; Figueras, A; Fornander, T; García, N; Garcia-Mata, R; Gil, M; Gómez-Baldó, L; Halonen, P; Islam, A; Jansen, MP; Karlsson, E; Katzenellenbogen, JA; Kiyotani, K; Martrat, G; Mushiroda, T; Nakamura, Y; Nevedomskaya, E; Pérez Tenorio, G; Pujana, MA; Rodríguez-Peña, AB; Rodríguez-Vida, A; Serra-Musach, J; Sgroi, DC; Soler, MT; Stål, O; Urruticoechea, A; Villanueva, A; Vizoso, M; Zembutsu, H; Zwart, W | 1 |
| Aparicio, AM; Bonnefous, C; Darimont, BD; Douglas, KL; Govek, SP; Grillot, KL; Hager, JH; Joseph, JD; Kahraman, M; Kaufman, JA; Lai, AG; Lee, KJ; Lu, N; Moon, MJ; Nagasawa, JY; Prudente, RY; Rix, PJ; Sensintaffar, J; Smith, ND | 1 |
| Aparicio, AM; Bonnefous, C; Darimont, BD; Douglas, KL; Govek, SP; Grillot, KL; Hager, JH; Joseph, JD; Julien, JD; Kahraman, M; Kaufman, JA; Lai, AG; Lee, KJ; Lu, N; Moon, MJ; Nagasawa, JY; Prudente, RY; Rix, PJ; Sensintaffar, J; Smith, ND | 1 |
| Chumakova, A; Esakov, EL; Gullapalli, K; Hale, J; Jensen, J; Lathia, J; Reizes, O; Richards, EG; Torre-Healy, L; Trivedi, D; Wessely, O | 1 |
| Furugen, A; Iseki, K; Kobayashi, M; Nadai, T; Narumi, K; Saito, Y | 1 |
| Ala-Hongisto, H; Bertula, K; Elo, LL; Euro, L; Heikkilä, P; Hollmann, B; Hukkinen, K; Ikkala, O; Joensuu, H; Junttila, MR; Kivento, M; Klefström, J; Kovanen, P; Leidenius, M; Martikainen, L; Mattson, J; Meretoja, T; Metcalfe, C; Monni, O; Munne, PM; Mutka, M; Nevalaita, L; Patrikainen, L; Peura, A; Pokki, J; Pouwels, J; Räty, I; Ruuska, J; Sahu, B; Salmela, M; Suomi, T; Väänänen, J; Yavuz, K | 1 |
1 trial(s) available for indazoles and tamoxifen
| Article | Year |
|---|---|
Lonidamine versus high-dose tamoxifen in progressive, advanced renal cell carcinoma: results of an ongoing randomized phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Evaluation; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Remission Induction; Survival Rate; Tamoxifen; Time Factors | 1991 |
9 other study(ies) available for indazoles and tamoxifen
| Article | Year |
|---|---|
Tamoxifen inhibits nitrotyrosine formation after reversible middle cerebral artery occlusion in the rat.
Topics: Animals; Brain; Cerebral Cortex; Disease Models, Animal; Enzyme Inhibitors; Indazoles; Ischemic Attack, Transient; Male; Middle Cerebral Artery; Nitrates; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Rats; Rats, Sprague-Dawley; Reference Values; Superoxides; Tamoxifen; Tyrosine | 2001 |
Myricitrin, a nitric oxide and protein kinase C inhibitor, exerts antipsychotic-like effects in animal models.
Topics: Animals; Antipsychotic Agents; Apomorphine; Arginine; Catalepsy; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Flavonoids; Indazoles; Male; Mice; Motor Activity; Nitric Oxide; Phytotherapy; Plant Leaves; Plant Preparations; Protein Kinase C; Psychotic Disorders; Rats; Rats, Wistar; Stereotyped Behavior; Syzygium; Tamoxifen | 2011 |
Contrasting hypoxic effects on breast cancer stem cell hierarchy is dependent on ER-α status.
Topics: Animals; Blotting, Western; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Estrogen Antagonists; Estrogen Receptor alpha; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Mammary Neoplasms, Experimental; MCF-7 Cells; Mice; Mice, Nude; Neoplastic Stem Cells; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Tamoxifen; Transplantation, Heterologous | 2013 |
VAV3 mediates resistance to breast cancer endocrine therapy.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Enzyme Activators; ErbB Receptors; Erlotinib Hydrochloride; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Genetic Association Studies; Genetic Variation; Humans; Indazoles; Letrozole; MCF-7 Cells; Nitriles; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-vav; Quinazolines; RNA Interference; RNA, Small Interfering; Tamoxifen; Toremifene; Triazoles | 2014 |
Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cinnamates; Drug Resistance, Neoplasm; Estrogen Receptor Antagonists; Female; Indazoles; Rats; Structure-Activity Relationship; Tamoxifen; Xenograft Model Antitumor Assays | 2015 |
Selective estrogen receptor degraders with novel structural motifs induce regression in a tamoxifen-resistant breast cancer xenograft.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; Cinnamates; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Indazoles; Mammary Neoplasms, Experimental; Mice; Molecular Structure; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Tamoxifen | 2019 |
Therapeutic strategies to induce ERα in luminal breast cancer to enhance tamoxifen efficacy.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Everolimus; Female; Humans; Hydroxamic Acids; Indazoles; MCF-7 Cells; Paclitaxel; Sulfonamides; Tamoxifen; Tumor Cells, Cultured | 2019 |
Pharmacological Inhibition of MCT4 Reduces 4-Hydroxytamoxifen Sensitivity by Increasing HIF-1α Protein Expression in ER-Positive MCF-7 Breast Cancer Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; MCF-7 Cells; Monocarboxylic Acid Transporters; Muscle Proteins; Propionates; Receptors, Estrogen; Tamoxifen | 2021 |
Compressive stress-mediated p38 activation required for ERα + phenotype in breast cancer.
Topics: Breast Neoplasms; Case-Control Studies; Cell Line, Tumor; Cinnamates; Collagen; Drug Combinations; Enhancer of Zeste Homolog 2 Protein; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histones; Humans; Indazoles; Laminin; Mammary Glands, Human; Mechanotransduction, Cellular; p38 Mitogen-Activated Protein Kinases; Phenotype; Proteoglycans; Tamoxifen; Tissue Culture Techniques; Transcriptome | 2021 |